BridgeBio Pharma BBIO 深 沪
等待开盘 08-17 09:30:00 美东时间
79.86
-1.350
-1.66%
华盛通- 最 高80.56
- 今 开80.14
- 成交量 309.40万股
- 最 低 78.60
- 昨 收 81.21
- 总市值 156.41亿
- 52周最高 93.415
- 市盈率 静 --
- 换手率 1.58%
- 52周最低 46.81
- 委 比 -33.33%
- 总股本 1.96亿
- 历史最高 93.415
- 量 比 1.26
- 振 幅 2.41%
- 历史最低 4.98
- 每 手 1
- 风险率 9.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BridgeBio discloses 5M share secondary offering by KKR affiliate
BridgeBio Pharma (BBIO) announced on Thursday the launch of a secondary public offering of 5M shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The company said it is not...
08-14 06:02
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
美股大行评级 | 潜在涨幅207.38%！Truist Securities上调AbCellera Biologics目标价至30美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持AbCellera Biologics"买入"评级，目标价从12美元升至30美元；Stifel：维持Proficient Auto Logistics"买入"评级，目标价从9美元升至12美元
08-12 08:45
Wells Fargo Maintains Overweight on BridgeBio Pharma, Raises Price Target to $102
Wells Fargo analyst Derek Archila maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $98 to $102.
08-11 20:57
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
BridgeBio Oncology Therapeutics (BBOT) reported progress in advancing its clinical programs for KRAS and PI3Kα inhibitors, including BBO-8520, BBO-11818, and BBO-10203. The company initiated dosing of BBO-11818 in combination therapies and presented promising preclinical data at AACR. Financially, BBOT had $344.1 million in cash as of June 2026, with a runway into 2028, though it reported a net loss of $56.5 million for the quarter.
08-11 20:05
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma announced equity grants of 66,705 restricted stock units to 56 new employees on August 8, 2026. The shares will vest quarterly over four years, with the first quarter vesting on August 16, 2027, contingent on continued employment. The grants were made under Nasdaq Listing Rule 5635(c)(4) and the Company’s amended equity plan. BridgeBio focuses on developing medicines for genetic conditions, aiming to bridge the gap between geneti...
08-11 20:01
财报速睇 | BridgeBio Pharma 2026财年Q2营收2.44亿美元，同比增长119.8%；归母净利润亏损1.52亿美元，同比亏损缩窄16.5%
华盛资讯8月11日讯，BridgeBio Pharma公布2026财年Q2业绩，公司Q2营收2.44亿美元，同比增长119.8%，归母净利润亏损1.52亿美元，同比亏损缩窄16.5%。
08-11 05:41
财报速睇 | BridgeBio Pharma 2026财年Q2营收2.44亿美元，同比增长119.8%；归母净利润亏损1.52亿美元，同比亏损缩窄16.3%
华盛资讯8月11日讯，BridgeBio Pharma公布2026财年Q2业绩，公司Q2营收2.44亿美元，同比增长119.8%，归母净利润亏损1.52亿美元，同比亏损缩窄16.3%。
08-11 04:48
BridgeBio Pharma Q2 EPS $(0.78) Misses $(0.59) Estimate, Sales $243.676M Beat $218.743M Estimate
BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.59) by 32.2 percent. This is a 17.89 percent increase over losses of $(0.95) per share from the same period last year. The company reported quarterly sales of $243.676 mil...
08-11 04:02
